Lenalidomide,polatuzumab vedotin,obinutuzumab
roche,bms
['lymphoma']
ph ib/ii pola-obi-lena in r/r fl n=56
heavily pre-treated (me prev lines 3, 1 7); refractory 59%; pod24 27% 100% at least one ae, 64% sae, 86% grade 3 4 after me follow-up 3.6y me pfs not reached. 53% progression free at 48mo extra! ctdna analysis done #lymphoma #ash22 
Medical degree at @USAL | Internal Medicine student at @HematoCAUSA | Hematology and Hemotherapy at Hospital Ramón y Cajal @HematoRYC | PhD student at @UAHes